A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA or reference ESAs.

Trial Profile

A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with MIRCERA or reference ESAs.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Methoxy polyethylene glycol-epoetin beta (Primary) ; Darbepoetin alfa; Epoetin beta; Erythropoietin
  • Indications Anaemia; Kidney disorders
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 15 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top